Tango Therapeutics, Inc. (TNGX)
NASDAQ$1.95
Market Cap
$210.81M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
318 of 924
Rank in Industry
184 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
TNGX Insider Trading Activity
TNGX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $74,000 | 2 | 5 |
Sells | $56,911,478 | 39 | 95 |
Related Transactions
| Rothenberg Mace | director | 2 | $74,000 | 0 | $0 | $74,000 |
| Barry Douglas | General Counsel | 0 | $0 | 2 | $16,369 | $-16,369 |
| Beckman Daniella | Chief Financial Officer | 0 | $0 | 2 | $25,282 | $-25,282 |
| Calhoun Lesley Ann | director | 0 | $0 | 1 | $36,039 | $-36,039 |
| Crystal Adam | See Remarks | 0 | $0 | 2 | $43,866 | $-43,866 |
| Weber Barbara | Chief Executive Officer | 0 | $0 | 2 | $57,710 | $-57,710 |
| MVA Investors, LLC | See remarks | 0 | $0 | 8 | $4.62M | $-4.62M |
| EcoR1 Capital, LLC | 10 percent owner | 0 | $0 | 2 | $8.44M | $-8.44M |
| Boxer Capital Management, LLC | See remarks | 0 | $0 | 4 | $20.12M | $-20.12M |
| Third Rock Ventures IV, L.P. | 10 percent owner | 0 | $0 | 16 | $23.55M | $-23.55M |
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with …
Insider Activity of Tango Therapeutics, Inc.
Over the last 12 months, insiders at Tango Therapeutics, Inc. have bought $74,000 and sold $56.91M worth of Tango Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tango Therapeutics, Inc. have bought $4.58M and sold $20.49M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rothenberg Mace (director) — $74,000.
The last purchase of 10,000 shares for transaction amount of $37,800 was made by Rothenberg Mace (director) on 2024‑11‑18.
List of Insider Buy and Sell Transactions, Tango Therapeutics, Inc.
| 2025-02-05 | Sale | Weber Barbara | Chief Executive Officer | 9,013 0.0087% | $3.16 | $28,494 | -31.34% | |
| 2025-02-05 | Sale | Crystal Adam | See Remarks | 6,851 0.0066% | $3.16 | $21,659 | -31.34% | |
| 2025-02-05 | Sale | Beckman Daniella | Chief Financial Officer | 3,948 0.0038% | $3.16 | $12,481 | -31.34% | |
| 2025-02-05 | Sale | Barry Douglas | General Counsel | 2,556 0.0025% | $3.16 | $8,081 | -31.34% | |
| 2025-02-04 | Sale | Weber Barbara | Chief Executive Officer | 9,778 0.0093% | $2.99 | $29,217 | -23.52% | |
| 2025-02-04 | Sale | Crystal Adam | See Remarks | 7,432 0.0071% | $2.99 | $22,207 | -23.52% | |
| 2025-02-04 | Sale | Beckman Daniella | Chief Financial Officer | 4,284 0.0041% | $2.99 | $12,801 | -23.52% | |
| 2025-02-04 | Sale | Barry Douglas | General Counsel | 2,774 0.0027% | $2.99 | $8,289 | -23.52% | |
| 2024-11-18 | Rothenberg Mace | director | 10,000 0.0098% | $3.78 | $37,800 | -15.56% | ||
| 2024-11-14 | Rothenberg Mace | director | 10,000 0.0088% | $3.62 | $36,200 | -22.45% | ||
| 2024-11-07 | Sale | EcoR1 Capital, LLC | 10 percent owner | 1.21M 1.1237% | $2.94 | $3.54M | +7.60% | |
| 2024-11-06 | Sale | EcoR1 Capital, LLC | 10 percent owner | 1.49M 1.3103% | $3.28 | $4.9M | -6.17% | |
| 2024-11-06 | Sale | Boxer Capital Management, LLC | See remarks | 3.08M 2.5882% | $3.14 | $9.67M | -6.17% | |
| 2024-10-25 | Sale | Boxer Capital Management, LLC | See remarks. | 633,000 0.6113% | $6.87 | $4.35M | -48.40% | |
| 2024-10-22 | Sale | Boxer Capital Management, LLC | See remarks | 250,000 0.2383% | $6.78 | $1.7M | -53.61% | |
| 2024-10-21 | Sale | Boxer Capital Management, LLC | See remarks | 625,000 0.5752% | $7.05 | $4.41M | -56.92% | |
| 2024-09-13 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 67,400 0.0631% | $10.53 | $709,756 | -69.24% | |
| 2024-09-05 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 75,000 0.0693% | $11.56 | $867,135 | -72.09% | |
| 2024-08-30 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 175,000 0.1601% | $11.60 | $2.03M | -71.85% | |
| 2024-08-27 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 25,000 0.0236% | $11.55 | $288,665 | -70.61% |
Total: 63
*Gray background shows transactions not older than one year
Insider Historical Profitability
29.82%
| Rothenberg Mace | director | 31250 0.0289% | $60,937.50 | 2 | 0 | |
| Boxer Capital, LLC | 8198642 7.5838% | $15.99M | 3 | 1 | +19.37% | |
| Davis Aaron I. | director | 7123642 6.5894% | $13.89M | 3 | 0 | +36.79% |
| LEWIS JOSEPH | director | 7053642 6.5246% | $13.75M | 3 | 0 | +40.76% |
| BCTG Holdings, LLC | 10 percent owner | 4488450 4.1518% | $8.75M | 1 | 1 | +7.42% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$21,574,635 | 88 | 2.81% | $211.87M | |
$7,150,333 | 87 | -8.28% | $221.99M | |
$613,304,943 | 46 | 11.85% | $181.55M | |
$48,218,096 | 42 | 0.89% | $210.73M | |
$2,545,071 | 34 | 16.59% | $241.88M |
TNGX Institutional Investors: Active Positions
| Increased Positions | 86 | +64.66% | 41M | +40.23% |
| Decreased Positions | 53 | -39.85% | 27M | -26.97% |
| New Positions | 44 | New | 39M | New |
| Sold Out Positions | 27 | Sold Out | 11M | Sold Out |
| Total Postitions | 166 | +24.81% | 115M | +13.26% |
TNGX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Trv Gp Iv, Llc | $32,875.00 | 15.61% | 16.86M | 0 | 0% | 2024-12-31 |
| Tcg Crossover Management, Llc | $20,935.00 | 9.94% | 10.74M | +11M | New | 2024-12-31 |
| Ecor1 Capital, Llc | $20,730.00 | 9.84% | 10.63M | -3M | -20.25% | 2024-12-31 |
| Boxer Capital Management, Llc | $20,243.00 | 9.61% | 10.38M | +10M | New | 2024-12-31 |
| Boxer Capital, Llc | $15,987.00 | 7.59% | 8.2M | 0 | 0% | 2024-09-30 |
| Nextech Invest Ltd. | $10,791.00 | 5.12% | 5.53M | 0 | 0% | 2024-12-31 |
| Gilead Sciences, Inc. | $9,466.00 | 4.5% | 4.85M | +5M | New | 2024-12-31 |
| Blackrock, Inc. | $8,538.00 | 4.05% | 4.38M | +17,168 | +0.39% | 2024-12-31 |
| Farallon Capital Management Llc | $7,800.00 | 3.7% | 4M | +4M | New | 2024-12-31 |
| Vanguard Group Inc | $7,771.00 | 3.69% | 3.99M | +339,922 | +9.32% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.